t
IXICO plc announced on 7 February 2025 the issue of share option awards covering a total of 7,413,488 shares. These options were approved by 99.76% of the shareholder vote at the Annual General Meeting on 24 January 2025. Chief Executive Officer Bram Goorden was granted 4,448,093 options and Chief Financial Officer Grant Nash was granted 2,965,395 options, both at 1 pence per option, on 7 February 2025.
| Date | 7 Feb 2025 |
| Time | 15:00:00 |
| Category | Director/PDMR dealings |
| ID | 3983W |
IXICO PLC
("IXICO" or the "Company")
Issue of share options
7 February 2025 - London, UK. IXICO plc (AIM: IXI, "IXICO" or "the Company") a global leader in neuroscience imaging, using its AI-driven platform to help advance therapy research in neurological disorders, confirms that share option awards covering 7,413,488 shares, which were proposed by, and discussed with, the Company's major shareholders in October 2024 (see: Circular) and approved pursuant to a resolution supported by 99.76% of the shareholder vote at the Annual General Meeting of 24 January 2025 have been issued today.
Full details of the terms of the options were set out in the Notice of AGM (see: AGM resolutions)
Ends
Further information:
|
IXICO plc |
+44 (0) 20 3763 7499 |
||
|
Bram Goorden, Chief Executive Officer Grant Nash, Chief Financial Officer |
|
||
|
|
|
||
|
Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker) |
+44 (0) 20 7220 0500 |
||
|
Giles Balleny / Dan Hodkinson (Corporate Finance) Nigel Birks (Life Science Specialist Sales) Harriet Ward (Corporate Broking) Michael F Johnson / Tamar Cranford Smith (Sales) |
|
|
|
About IXICO www.IXICO.com
IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.
IXICO has developed and deployed breakthrough data analytics, at scale, through its remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
|
a)
|
Name
|
Bram Goorden |
|||
|
2
|
Reason for the notification
|
||||
|
a)
|
Position/status
|
Chief Executive Officer |
|||
|
b)
|
Initial notification /Amendment
|
Initial |
|||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
IXICO plc |
|||
|
b)
|
LEI
|
2138005M1F59O6HWSA97 |
|||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
|
a)
|
Description of the financial instrument, type of instrument |
Options over ordinary shares in IXICO plc
|
|||
|
|
|
||||
|
Identification code |
ISIN: GB00BFXR4C20 |
||||
|
|
|
||||
|
b)
|
Nature of the transaction
|
Grant of Share Options |
|||
|
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
1 pence |
4,448,093 |
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information |
|
|||
|
|
|
||||
|
- Aggregated volume |
|
||||
|
|
|
||||
|
- Price |
|
||||
|
|
|
||||
|
e)
|
Date of the transaction
|
7 February 2025 |
|||
|
f)
|
Place of the transaction
|
Off Market Transaction |
|||
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
|
a)
|
Name
|
Grant Nash |
|||
|
2
|
Reason for the notification
|
||||
|
a)
|
Position/status
|
Chief Financial Officer |
|||
|
b)
|
Initial notification /Amendment
|
Initial |
|||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
IXICO plc |
|||
|
b)
|
LEI
|
2138005M1F59O6HWSA97 |
|||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
|
a)
|
Description of the financial instrument, type of instrument |
Options over ordinary shares in IXICO plc
|
|||
|
|
|
||||
|
Identification code |
ISIN: GB00BFXR4C20 |
||||
|
|
|
||||
|
b)
|
Nature of the transaction
|
Grant of Share Options |
|||
|
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
1 pence |
2,965,395 |
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information |
|
|||
|
|
|
||||
|
- Aggregated volume |
|
||||
|
|
|
||||
|
- Price |
|
||||
|
|
|
||||
|
e)
|
Date of the transaction
|
7 February 2025 |
|||
|
f)
|
Place of the transaction
|
Off Market Transaction |
|||